KIT and acute myeloid leukemia: Using two cell models of c-Kit-N822K-mutated CBF-AML, we demonstrated that both pharmacological and genetic FASN inhibition resulted in the rewiring of c-Kit-associated pathways, particularly with a significant upregulation of p-c-Kit, pLyn, pMAPK, and pS6.